glp 1 drugs and parkinson's disease Neuroprotective effects of GLP-1 class in GLP-1 Drugs and Parkinson's Disease:

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications originally developed for type 2 diabetes management and now widely prescribed for chronic weight management

Non-Pharmaceutical Options Lifestyle interventions Structured diet plans, regular physical activity, and behavioural therapy

Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats

V., Wu, B., Liu, Y

[DOI] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article.

None of these medications should be used during pregnancy or breastfeeding